Busulfan and Cyclophosphamide Followed By ALLO BMT
NCT01685411
Terminated
This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
Gender:
ALL
Ages:
44 years and below
Trial Updated:
03/17/2021
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Register for Updates
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
NCT02225665
Completed
The purpose of this study is to evaluate the safety and tolerability of repeat doses of T-cell immunotherapy (SB-728mR-T) following cyclophosphamide conditioning. CCR5 is a major co-receptor for HIV entry into T-cells. Disruption of CCR5 by zinc finger nuclease (SB-728mR), blocks HIV entry into the T-cells, therefore, protects the T-cells from HIV infection. Safety (primary outcome) and anti-viral effect (secondary outcome) of zinc finger nuclease-mediated CCR5 disrupted autologous T-cells (SB-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2021
Locations: Not set, San Francisco, California +4 locations
Conditions: Human Immunodeficiency Virus (HIV)
Register for Updates
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
NCT01045460
Completed
Patient Population: Patients with active myeloma (Stage II/III) that have completed induction therapy and are eligible for an autologous stem cell transplant. Number of Patients: Will treat a total of 32 evaluable patients in a 1:1 randomization of aMILs vs aMILs plus vaccine. An evaluable patient is defined as one which has received the activated MILs and is at least 6 months post-transplant. Study Objectives: Disease response as determined by the Blade' criteria will be the primary endpoint... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/16/2021
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Multiple Myeloma
Register for Updates
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
NCT01338987
Completed
Background: * One way to treat certain cancers of the blood and immune system is to give a patient stem cells from the bone marrow of a donor whose genes are very similar but not identical to the patients. One problem with these transplants is that the new immune cells may not work as well in the recipient as they did in the donor. The result may be that the immune system will not work as well. This can increase the risk of severe infections and other complications. * Researchers are studying t... Read More
Gender:
ALL
Ages:
Between 4 years and 55 years
Trial Updated:
03/16/2021
Locations: Childrens National Medical Center, Washington, District of Columbia +2 locations
Conditions: Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
Register for Updates
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
NCT01967823
Completed
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying them, and then giving the cells back to the patient. In a previous study the NCI Surgery Branch used the anti-ESO-1 gene and a type of virus (retrovirus) to make these tumor fighting cells (anti-ESO-1 cells). About half of the patients... Read More
Gender:
ALL
Ages:
Between 15 years and 70 years
Trial Updated:
03/01/2021
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer
Register for Updates
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
NCT00112827
Completed
RATIONALE: Melphalan, a chemotherapeutic agent, has been found to be an effective treatment choice for destroying myeloma cells, especially when given at high (bone marrow ablative) doses. Total marrow irradiation (TMI)/ablative dose radiation therapy is another modality capable of destroying myeloma cells. Autologous peripheral blood/stem cell transplant (ASCT) given after either melphalan or following TMI (aimed at the bone marrow containing areas of the skeleton, the site of origin of myeloma... Read More
Gender:
ALL
Ages:
70 years and below
Trial Updated:
02/25/2021
Locations: City of Hope Medical Center, Duarte, California
Conditions: Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Register for Updates
Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
NCT00002611
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney canc... Read More
Gender:
ALL
Ages:
Between 0 years and 15 years
Trial Updated:
02/23/2021
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +234 locations
Conditions: Kidney Cancer
Register for Updates
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
NCT00439296
Terminated
This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemot... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/22/2021
Locations: Childrens Hospital Los Angeles, Los Angeles, California +4 locations
Conditions: Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL
Register for Updates
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
NCT02981524
Completed
This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/08/2021
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Metastatic Colorectal Cancer
Register for Updates
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00004031
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation and kill more cancer cells. It is not yet known whether chemoradiotherapy plus peripheral stem cell transplantation is more effective than combination chemotherapy alone in treating non-Hodgkin's lymphoma... Read More
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
01/29/2021
Locations: Oregon Health & Science University, Portland, Oregon +14 locations
Conditions: Lymphoma
Register for Updates
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
NCT00470301
Completed
Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving tipifarnib together with combination chemotherapy may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2021
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida +6 locations
Conditions: Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Register for Updates
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
NCT04536922
Withdrawn
Background: A cancer treatment has been developed called "gene transfer" or "gene therapy." It involves taking white blood cells from a person (called apheresis), genetically modifying the cells in a lab to recognize cancer, and then giving the cells back to the person. Researchers want to see if this treatment can help people with metastatic squamous cell anal cancer. Objective: To see if treating cancer with a person s own white blood cells that have been genetically modified can cause tumo... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/29/2021
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastatic HPV-16 Positive Squamous Cell Anal Cancer
Register for Updates